surotomycin and Enterobacteriaceae-Infections

surotomycin has been researched along with Enterobacteriaceae-Infections* in 1 studies

Other Studies

1 other study(ies) available for surotomycin and Enterobacteriaceae-Infections

Article	Year
In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species. Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3 MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were >8,192, 8,192, and 4 μg/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were >8,192 μg/ml, 1,024 μg/ml, and 1,024 μg/ml, respectively. The CB-183,315 MIC(90) for Clostridium difficile was 0.5 μg/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile. Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Clostridioides difficile; Enterobacteriaceae; Enterobacteriaceae Infections; Enterocolitis, Pseudomembranous; Humans; Intestines; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Peptides, Cyclic; Vancomycin	2012

Article

Year

In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.

Antimicrobial agents and chemotherapy, 2012, Volume: 56, Issue:3

MICs of CB-183,315, a novel lipopeptide antibiotic, vancomycin, and metronidazole were determined for intestinal anaerobes and Enterobacteriaceae. The MIC(90)s for Gram-negative anaerobes were >8,192, 8,192, and 4 μg/ml for CB-183,315, vancomycin, and metronidazole, respectively. Against Enterobacteriaceae, the MIC(90)s were >8,192 μg/ml, 1,024 μg/ml, and 1,024 μg/ml, respectively. The CB-183,315 MIC(90) for Clostridium difficile was 0.5 μg/ml. Its lack of activity against normal fecal organisms makes it a promising new agent for treating C. difficile.

Topics: Anti-Bacterial Agents; Bacteria, Anaerobic; Clostridioides difficile; Enterobacteriaceae; Enterobacteriaceae Infections; Enterocolitis, Pseudomembranous; Humans; Intestines; Lipopeptides; Metronidazole; Microbial Sensitivity Tests; Peptides, Cyclic; Vancomycin

2012